文献速递自身炎症与 IgG4 相关病

家族性地中海热诊断时预测秋水仙碱抵抗的评分:来自TURPAID登记处的数据

A score for predicting colchicine resistance at the time of diagnosis in familial Mediterranean fever: data from the TURPAID registry.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

基于土耳其儿童自身炎症性疾病登记处3445例家族性地中海热(FMF)患者(256例秋水仙碱抵抗,3189例秋水仙碱敏感),比较两组特征并开发预测秋水仙碱抵抗的评分。多因素分析显示发病年龄、发作频率、关节炎、胸痛及携带两个外显子10 MEFV突变是最强预测因子,评分在训练队列敏感度81.3%、特异度49.1%,验证队列敏感度93.5%、特异度53.8%。作者认为该评分有助于在诊断时识别秋水仙碱抵抗高风险患者并个体化调整管理。

要点

  • 秋水仙碱抵抗患者相比敏感患者发作更长更频繁、症状出现及诊断年龄更小(P < 0.05)。
  • 发热、丹毒样红斑、关节痛、关节炎、肌痛、腹痛、腹泻、胸痛、合并症、父母近亲婚配及外显子10 MEFV突变纯合/复合杂合在抵抗组更常见(P < 0.05)。
  • 预测评分包含发病年龄、发作频率、关节炎、胸痛及携带两个外显子10突变,训练队列敏感度81.3%、特异度49.1%,验证队列敏感度93.5%、特异度53.8%。

核心结论

  • 作者开发了一个临床友好且实用的预测评分,可帮助在诊断时识别秋水仙碱抵抗风险较高的FMF患者并个体化调整疾病管理。

研究设计与样本

  • 研究纳入土耳其儿童自身炎症性疾病(TURPAID)登记处0-18岁FMF患者,使用单变量/多变量回归和受试者工作特征分析开发秋水仙碱抵抗预测评分。

主要发现

  • 共纳入3445例FMF患者,其中秋水仙碱抵抗256例(7.4%)、秋水仙碱敏感3189例(女性:男性比1.02;诊断时中位年龄67.4个月)。
  • 秋水仙碱抵抗患者发作更长、更频繁,症状出现及诊断年龄更小(P < 0.05)。
  • 发热、丹毒样红斑、关节痛、关节炎、肌痛、腹痛、腹泻、胸痛、合并症、父母近亲婚配及外显子10 MEFV突变纯合/复合杂合在秋水仙碱抵抗组较敏感组更常见(P < 0.05)。
  • 训练队列(n = 2684)多变量logistic回归显示,症状出现年龄、发作频率、关节炎、胸痛及携带两个外显子10突变是秋水仙碱抵抗的最强预测因子。
  • 包含上述项目的评分在训练队列敏感度81.3%、特异度49.1%;在验证队列(n = 671)敏感度93.5%、特异度53.8%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Colchicine forms the mainstay of treatment in FMF. Approximately 5-10% of FMF patients are colchicine resistant and require anti-IL-1 drugs. We aimed to compare the characteristics of colchicine-resistant and colchicine-responsive patients and to develop a score for predicting colchicine resistance at the time of FMF diagnosis. METHODS: FMF patients (0-18 years) enrolled in the Turkish Paediatric Autoinflammatory Diseases (TURPAID) registry were included. The predictive score for colchicine resistance was developed by using univariate/multivariate regression and receiver operating characteristics analyses. RESULTS: A total of 3445 FMF patients [256 (7.4%) colchicine-resistant and 3189 colchicine-responsive) were included (female:male ratio 1.02; median age at diagnosis 67.4 months). Colchicine-resistant patients had longer, more frequent attacks and were younger at symptom onset and diagnosis (P < 0.05). Fever, erysipelas-like erythema, arthralgia, arthritis, myalgia, abdominal pain, diarrhoea, chest pain, comorbidities, parental consanguinity and homozygosity/compound heterozygosity for exon 10 MEFV mutations were significantly more prevalent among colchicine-resistant than colchicine-responsive patients (P < 0.05). Multivariate logistic regression analysis in the training cohort (n = 2684) showed that age at symptom onset, attack frequency, arthritis, chest pain and having two exon 10 mutations were the strongest predictors of colchicine resistance. The score including these items had a sensitivity of 81.3% and a specificity of 49.1%. In the validation cohort (n = 671), its sensitivity was 93.5% and specificity was 53.8%. CONCLUSION: We developed a clinician-friendly and practical predictive score that could help us identify FMF patients with a greater risk of colchicine resistance and tailor disease management individually at the time of diagnosis.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Batu ED, Şener S, Arslanoglu Aydin E, et al. A score for predicting colchicine resistance at the time of diagnosis in familial Mediterranean fever: data from the TURPAID registry. Rheumatology (Oxford). 2024. PMID: 37228026. doi:10.1093/rheumatology/kead242

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。